Glucose Health, Inc. (GLUC) presents a deeply negative liquidation posture as of September 30, 2017. Total assets of $26,353 face total liabilities of $452,585 at face value, producing a book stockholders' deficit of ($426,232). Under liquidation haircuts, the recovery picture is marginally worse than book: cash of $16,636 recovers at 100% ($16,636); accounts receivable of $9,105 recovers at approximately 90-95% ($8,195-$8,650) — the AR is concentrated almost entirely in Walmart, factored through a Citibank non-recourse facility, which is favorable for collectability but note that $3,150 of bad debt expense was recognized in the nine-month period; prepaid expenses of $417 return zero in liquidation; and intellectual property of $195 (net book value, carried at nominal historical cost of related-party transaction, amortized over ten years) returns zero. Total liquidation asset recovery is approximately $24,800-$25,300. Against $452,585 in face-value liabilities, estimated equity recovery is approximately ($427,000) to ($428,000), consistent with MFFAIS CLV/LLV of approximately ($426,000-$436,000). The liability stack is entirely current and consists of: accounts payable and accrued expenses $78,279; accrued interest $41,429; related-party note payable $35,000 (matured December 2016, at 24% — in default); third-party notes payable $10,000; related-party convertible notes $112,157 (5%, fixed conversion price $0.011); third-party convertible notes $159,220 (5%, fixed conversion price $0.008); other notes payable $16,500 (several past maturity). The convertible notes carry fixed sub-penny conversion prices, meaning approximately 34 million dilutive shares overhang any equity recovery calculation. The $35,000 related-party note has been in default since December 31, 2016, with no evidence of formal waiver or restructuring. Compared to the prior filing (Q2 2017, period ended June 30, 2017), total liabilities decreased from $476,607 to $452,585, driven primarily by a vendor accounts payable settlement ($58,131 gain YTD on forgiveness of payables, reducing AP from $138,134 at December 31, 2016 to $78,279). Accrued interest increased from $37,997 (Q2) to $41,429 (Q3), continuing to accrue on all outstanding notes. No inventory appears on the September 30, 2017 balance sheet — the filing discloses 4,927 units on hand valued at $0, consistent with FIFO lower-of-cost-or-market write-down. The Company has a going concern qualification. Filing discusses inventory valued at zero in footnotes but does not separately XBRL-tag inventory on the balance sheet face. Material weakness in internal controls remains unremediated.
▼ Community Notes